SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has healthcare providers who are specially trained in the insertion and removal of Probuphine® (buprenorphine

SAN FRANCISCO, Oct. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team:  Jonathan Zalevsky, Ph.D. has been promoted to Chief Research & Development Officer Gil M. Labrucherie has been prom

NEW YORK, Oct. 1, 2019 /PRNewswire/ -- Koneksa Health, a private company that enables the biopharmaceutical industry to develop new medicines using digital biomarkers and novel clinical endpoints, announced today the publication of a peer-reviewed manuscript demonstrating the utility of  wearable devices for monitoring clinical-trial subjects for physiological

BOSTON, Oct. 1, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer, will present at the 2019 C

LOS ANGELES, Oct. 1, 2019 /PRNewswire/ -- Today, Antech Diagnostics, part of Mars Petcare, released a new diagnostic tool that was developed using artificial intelligence to analyze pet medical record data to predict whether a cat will develop chronic kidney disease (CKD) up to two years before traditional clinical diagnosis.

MONTREAL, Oct. 1, 2019 /PRNewswire/ - Chronometriq, the Montreal-based provider of access-to-ca

ATLANTA, Oct. 1, 2019 /PRNewswire/ -- Advanced Medical Pricing Solutions (AMPS) announced today that 2019 was a year of aggressive, if behind-the-scenes, growth for the company. Under the leadership of Kirk Fallbacher, AMPS CEO and President, the pioneer in cost containment has stayed singularly focused on building out the infrastructure an

SALT LAKE CITY, Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") will be presented at

NEW YORK, Oct. 1, 2019 /PRNewswire/ -- Hospital for Special Surgery (HSS), world leader in orthopedics and rheumatology, has appointed an expert in healthcare transformation to lead an emerging musculoskeletal ecosystem propelled by HSS expertise, knowledge and care delivery. HSS president and CEO Louis A. Shapiro today announced the appoin

HOUSTON, Oct. 1, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced it has completed all patient treatments in t